Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer

Inclusion Criteria

• •1. Pathologically confirmed adenocarcinoma of the pancreas.
• •2. Patients must have locally advanced/unresectable disease based on institutional standardized criteria of unresectability.
• •3. Patients with residual disease after resection (R-1 or -2, micro and macroscopic residual) are eligible.
• •4. Patients with biliary or gastroduodenal obstruction must have drainage prior to starting chemoradiation.
• •5. All malignant disease must be encompassed within a single irradiation field (12 x 12 cm maximum).
• •6. All patients must have radiographically assessable disease.
• •7. Electrocardiogram (EKG), chest x-ray, abdominal computed tomography (CT)/magnetic resonance imaging (MRI) scan must be obtained within four weeks of study entry.
• •8. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
• •9. Required entry laboratory parameters: granulocytes \>/= 1,800/µl, platelet count \>/= 100,000/µl, bilirubin \< 2.0 mg/dL, alanine aminotransferase (ALT) \< 3 x upper limit of normal, and creatinine \< 3.0 mg/dL.
• •10. Signed study-specific consent form prior to study entry.